Study Summary
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.
Interested in this trial?
Submit an InquiryInterventions
U32 CAR-TDRUG
Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of Soochow University, Suzhou, JiangSu 215000 Recruiting | Suzhou | China |